Cooley M&A

OCTOBER 19, 2022

Cooley’s M&A practice has been busy amid the typically slower summer wind down. Steaming through the third quarter, Cooley’s deal flow put us at the top of the Bloomberg, Mergermarket and Refinitiv Q3 M&A league tables. Transfer Traps: Considerations for Dual-Class Companies Contemplating M&A Transactions.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

Cooley M&A

JANUARY 23, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

M&A Leadership Council

AUGUST 15, 2022

Fundamentals of M&A: An Excerpt from The Art of M&A Book Series. By Alexandra Reed Lajoux, Board of M&A Standards/Founding Principal at CapEx . How Common are Postmerger Divestitures of Acquired Company Units? . It depends on how long a timeline for divestiture you are considering. What is a sell-off? .

Mergers and Acquisitions 52

Mergers and Acquisitions IPO M&A Initial Public Offering 52

Cooley M&A

JANUARY 30, 2024

8] M&A-themed campaigns (sell the company/division or agitation against an announced transaction) made up 49% of all activism campaigns globally, well above the trailing four-year average of 42%. [9] 9] We expect the prevalence of M&A-themed campaigns to remain elevated in 2024 as M&A levels bounce back from 2023 levels.

Private Equity 52

Private Equity M&A Capital Investors 52